Medicare Coverage for Heart Failure: 2025 Guide
Heart failure affects over 6 million Americans and is the leading cause of hospitalization for Medicare beneficiaries over 65. Despite advances in treatment, heart failure carries a high readmission rate — and Medicare has strong financial incentives to reduce those readmissions. Here's what Medicare covers across the full spectrum of heart failure care, including a recently expanded cardiac rehab benefit and new medications that are transforming outcomes.
Heart Failure Coverage Quick Reference
| Service | Part | Your Cost (2025) | Notes |
|---|---|---|---|
| Cardiologist visits (HF management) | Part B | 20% after $257 deductible | Regular specialist monitoring required |
| Echocardiogram | Part B | 20% after deductible | Assesses ejection fraction and cardiac structure |
| BNP / NT-proBNP lab test | Part B | 20% after deductible | Key HF biomarker for diagnosis and monitoring |
| Hospitalization for HF exacerbation | Part A | $1,676 deductible per benefit period | Very common — HF is #1 cause of Medicare hospitalization |
| Cardiac rehabilitation (HFrEF, EF ≤35%) | Part B | 20% after deductible | Newly expanded to include stable CHF; 36–72 sessions |
| Remote patient monitoring (weight, symptoms) | Part B | 20% after deductible | Daily weight/symptom tracking with physician review |
| CardioMEMS pulmonary artery monitor | Part B | 20% after deductible | Implantable PA pressure sensor; wireless monitoring; reduces hospitalizations |
| ICD (implantable cardioverter-defibrillator) | Part A | $1,676 deductible | For EF ≤35% with high sudden death risk; implanted inpatient |
| CRT-D (cardiac resynchronization + defibrillator) | Part A | $1,676 deductible | For HF with LBBB and wide QRS; improves cardiac synchrony |
| LVAD (left ventricular assist device) | Part A | $1,676 deductible | Mechanical pump for advanced HF; bridge to transplant or destination therapy |
| Heart transplant evaluation & surgery | Part A | $1,676 deductible | At Medicare-certified transplant center |
| ACE inhibitors / ARBs (lisinopril, losartan) | Part D | Tier 1 generic; very low cost | Foundation of HFrEF treatment |
| Beta blockers (carvedilol, metoprolol succinate) | Part D | Tier 1 generic; very low cost | Mortality benefit proven in HFrEF |
| Spironolactone / eplerenone (MRAs) | Part D | Tier 1–2 generic | Aldosterone antagonists; proven mortality benefit |
| Sacubitril/valsartan (Entresto) | Part D | Tier 3–4; OOP cap $2,000 | Superior to ACE inhibitors for HFrEF; brand only until ~2025–2026 |
| SGLT2 inhibitors (dapagliflozin/Farxiga, empagliflozin/Jardiance) | Part D | Tier 2–3; OOP cap $2,000 | Now FDA-approved for HF regardless of diabetes status; significant outcomes benefit |
| Loop diuretics (furosemide, torsemide) | Part D | Tier 1 generic; very low cost | Symptom management; fluid removal |
| Digoxin | Part D | Tier 1 generic; <$5/month | Used for rate control and symptom improvement |
| IV diuretics / vasoactive drugs (hospitalized) | Part A | Covered under inpatient stay | Furosemide IV, dobutamine, milrinone during acute decompensation |
| Home health (post-hospitalization) | Part A/B | $0 for covered services | Skilled nursing, PT/OT when homebound post-discharge |
| Telehealth follow-up | Part B | 20% after deductible | Post-discharge HF monitoring via telehealth |
The 30-Day Readmission Problem — and What It Means for Your Care
Heart failure has one of the highest 30-day readmission rates of any condition. Approximately 25% of hospitalized heart failure patients are readmitted within 30 days. This is not just a quality issue — it directly affects what happens to you after discharge.
Under the Hospital Readmissions Reduction Program (HRRP), Medicare financially penalizes hospitals with excessive heart failure readmission rates. This creates strong incentives for hospitals to:
- Arrange close follow-up appointments within 7–14 days of discharge
- Provide clear medication instructions and weight-monitoring guidance
- Refer patients to heart failure clinics or case management programs
- Enroll patients in remote monitoring programs
What this means for you: Before you leave the hospital after a heart failure admission, make sure you have a follow-up appointment scheduled within 1–2 weeks, you understand your "dry weight" and when to call your doctor (typically gain of 2–3 lbs in 24 hours or 5 lbs in a week), and you have all medications filled at the hospital pharmacy before discharge.
SGLT2 Inhibitors: The Drug Class Transforming HF Outcomes
SGLT2 inhibitors — originally developed as diabetes medications — have been proven to reduce hospitalizations and mortality in heart failure patients, even those without diabetes. Medicare Part D covers them for heart failure:
- Dapagliflozin (Farxiga): FDA-approved for HFrEF and HFpEF (all ejection fractions) regardless of diabetes status
- Empagliflozin (Jardiance): FDA-approved for HFrEF; also has HFpEF data
These are Tier 2–3 drugs under most Part D plans — they aren't generic yet. But with the 2025 $2,000 OOP cap, the maximum you'll spend on all Part D drugs combined is $2,000 — significantly reducing the financial barrier for patients who also take expensive medications like Entresto.
Cardiac Rehabilitation for Heart Failure
Medicare expanded cardiac rehab coverage to include stable chronic heart failure with ejection fraction ≤35% (NYHA Class II–III). This is a significant benefit that was not available to heart failure patients until recently.
What cardiac rehab provides for heart failure patients:
- Supervised exercise training tailored to heart failure physiology
- Education about fluid management, sodium restriction, and weight monitoring
- Medication education
- Psychosocial support (depression is common in heart failure patients)
- Up to 36 sessions per benefit period, extendable to 72 with documentation
Coverage: Part B at 20% coinsurance after the deductible. Medigap Plan G covers the 20%.
CardioMEMS: Implantable Pulmonary Artery Monitoring
The CardioMEMS HF System is a wireless sensor implanted in the pulmonary artery that continuously monitors pulmonary artery pressures — a key indicator of worsening heart failure before symptoms appear. Clinical trials showed a 28% reduction in heart failure hospitalizations.
Medicare covers CardioMEMS implantation and ongoing monitoring for patients who:
- Have NYHA Class III heart failure
- Have been hospitalized for heart failure in the past year
The implantation is an outpatient cardiac catheterization procedure. Ongoing monthly monitoring is covered under Part B remote monitoring codes. Ask your cardiologist if you qualify.
Advanced Heart Failure: LVAD and Transplant
For patients with end-stage or advanced heart failure refractory to optimal medical therapy, Medicare covers the most intensive interventions:
Left Ventricular Assist Device (LVAD)
- A mechanical pump implanted to assist the weakened left ventricle
- Used as bridge-to-transplant (while awaiting a donor heart) or destination therapy (permanent, in transplant-ineligible patients)
- Covered under Part A at Medicare-certified VAD implantation centers
- Ongoing LVAD management and driveline care covered through home health and outpatient care
Heart Transplant
- Covered under Part A at Medicare-certified transplant centers
- Post-transplant immunosuppressive medications covered under Part B and Part D
- Part D OOP cap of $2,000/year applies to post-transplant drug costs
Frequently Asked Questions
Yes — but only for stable chronic heart failure with an ejection fraction of 35% or less (HFrEF), NYHA Class II or III. This coverage was recently expanded and is not available for all heart failure patients. If your EF is above 35% (HFpEF), you currently do not qualify for Medicare-covered cardiac rehab, though some Medicare Advantage plans may offer it. Talk to your cardiologist about whether you qualify and can get a referral.
Yes. Sacubitril/valsartan (Entresto) is covered under Medicare Part D. It's typically a Tier 3–4 drug since it's brand-only (generic versions are in development). At its list price, Entresto previously cost patients thousands annually in Part D cost-sharing. Starting in 2025, the $2,000 Part D OOP cap applies — meaning your maximum out-of-pocket spending on all Part D drugs is $2,000/year, regardless of Entresto's cost. Compare Part D plans during Annual Election Period to find the plan with the best Entresto coverage.
Yes. Medicare covers implantable cardioverter-defibrillators (ICDs) for heart failure patients with ejection fraction ≤35% who are at high risk for sudden cardiac death. This typically includes patients who have had a heart attack or have nonischemic cardiomyopathy and have been on optimal medical therapy for at least 3 months. The implantation is an inpatient procedure covered under Part A (the $1,676 Part A deductible applies). Medigap Plan G covers that deductible. CRT-D devices (combining defibrillation with cardiac resynchronization) are also covered for patients with wide QRS and left bundle branch block.